超声心动图三维斑点追踪技术对乳腺癌曲妥珠单抗治疗中心脏毒性评估的应用

宋文娟; 马雪娟; 孙钺; 谷颖; 叶雨佳; 李姝墨; 葛菲; 刘利萍; 赵月; 王钰

doi:10.12259/j.issn.2095-610X.S20230217

超声心动图三维斑点追踪技术对乳腺癌曲妥珠单抗治疗中心脏毒性评估的应用

doi: 10.12259/j.issn.2095-610X.S20230217

宋文娟¹,
马雪娟¹,
孙钺¹,
谷颖¹,
叶雨佳¹,
李姝墨²,
葛菲²,
刘利萍¹,
赵月¹,
王钰^1, ,

1.
昆明医科大学第一附属医院心内科，云南昆明　650032
2.
昆明医科大学第一附属医院乳腺外科，云南昆明　650032

基金项目: 云南省卫健委临床医学中心建设项目（ZX2019-03-01）

详细信息

作者简介:
宋文娟（1977～），女，云南昆明人，硕士研究生，副主任医师，主要从事超声心动图工作

通讯作者:
王钰，E-mail：59899947@qq.com

中图分类号: R737.9
计量
- 文章访问数: 5085
- HTML全文浏览量: 2231
- PDF下载量: 7
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-14
- 网络出版日期: 2023-02-01
- 刊出日期: 2023-02-25

Evaluation of Cardiotoxicity in Trastuzumab Treatment of Breast Cancer Using Three-dimensional Speckle Tracking Echocardiography

1.
Dept. of Cardiology，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032
2.
Dept. of Breast Surgery，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032 ，China

摘要

摘要: 目的探讨超声心动图三维斑点追踪技术对乳腺癌曲妥珠单抗治疗中心脏毒性评估的应用。方法选取昆明医科大学第一附属医院2020年11月至2022年7月收治的应用曲妥珠单抗治疗乳腺癌患者65例，分别在治疗后3个月、6个月、9个月、12个月后给予常规超声心动图及三维斑点追踪技术（three-dimensional speckle tracking technique，3D-STI），观察不同时间点的心脏指标参数的差异，包括左室射血分数（LVEF）、左房容积指数（LAVI）、二尖瓣舒张早期血流速度/二尖瓣环舒张早期移动速度（E/Em）、二尖瓣环舒张早期移动速度/二尖瓣环舒张晚期移动速度（Em/Am）、二尖瓣环收缩期移动速度（Sm）、二尖瓣舒张早期血流速度（E峰）、二尖瓣舒张晚期血流速度（A峰）、二尖瓣舒张早期环移动速度（Em）、二尖瓣舒张晚期环移动速度（Am）、左室扭转（LVtw）、左室整体纵向应变（GLS）、整体环周应变（GCS）、整体径向应变（ GRS）、整体面积应变GAS ）指标。结果治疗后3个月、6个月、9个月、12个月相关参数和治疗前相比，LAVI、E/Em、Am有所升高，Em/Am和Em有所下降，LAVI和E/Em之间呈正相关性；与治疗前相比，治疗后3个月、6个月、9个月、12个月的LVEF、GLS、GRS、LVtw、GCS、GAS均有所下降（P < 0.05）。结论乳腺癌患者应用曲妥珠单抗治疗时应用超声心动图三维斑点追踪技术效果理想，可以早期、准确对心脏毒性情况进行判断，可以为早期治疗提供参考依据，改善预后、临床结局方面价值显著。
- 超声心动图 /
- 三维斑点追踪技术 /
- 乳腺癌 /
- 曲妥珠单抗 /
- 心脏毒性 /
- 评估
Abstract: Objective To investigate the application of three-dimensional speck tracking echocardiography in the evaluation of cardiotoxicity in trastuzumab treatment of breast cancer. Methods A total of 65 breast cancer patients treated with trastuzumab in the First Affiliated Hospital of Kunming Medical University from November 2020 to July 2022 were selected. Conventional echocardiography and three-dimensional speckle tracking technique （3D-STI） were performed 3, 6, 9, and 12 months after treatment. The differences in cardiac parameters at different time points were observed. The parameters included left ventricular ejection fraction （LVEF）, left atrial volume index （LAVI）, early diastolic mitral flow velocity/early diastolic mitral annular flow velocity （E/Em）, early diastolic mitral annular flow velocity/late diastolic mitral annular flow velocity （Em/Am）, early diastolic mitral annular flow velocity （Sm）, and early diastolic mitral annular flow velocity （E/Em）. Peak E）, peak late diastolic mitral flow velocity （peak A）, early diastolic mitral annular velocity （Em）, late diastolic mitral annular velocity （Am）, left ventricular torsion （LVtw）, global longitudinal strain （GLS）, global circumferential strain （GCS）, global radial strain （GRS）, global area strain （GAS）. Results Compared with those before treatment, LAVI, E/Em and Am increased 3 months, 6 months, 9 months, and 12 months after treatment, while Em/Am and Em decreased. LAVI and E/Em were positively correlated. Compared with before and after treatment, LVEF, GLS, GRS, LVtw, GCS and GAS decreased 3, 6, 9 and 12 months after treatment （P < 0.05）. Conclusions The application of three-dimensional echocardiographic speck tracking technology in the treatment of breast cancer patients with trastuzumab has an ideal effect, which can judge the cardiotoxicity more early and accurately, provide a reference for early treatment, and has value in improving prognosis and clinical outcome.
- Echocardiography /
- Three-dimensional speckle tracking technology /
- Breast cancer /
- Trastuzumab /
- Cardiotoxicity /
- Assessment

HTML全文

表 1 不同治疗周期常规超声心动图心脏指标（$\bar x \pm s $）

Table 1. Cardiac parameters of conventional echocardiography in different treatment cycles （$\bar x \pm s $）

指标	治疗前	治疗3个月	治疗6个月	治疗9个月	治疗12个月	F	P
LVEF（%）	66.18 ± 3.99	66.13 ± 3.91	65.99 ± 3.88	65.92 ± 3.69	65.81 ± 3.55	1.215	0.852
E（cm/s）	76.62 ± 3.27	76.53 ± 13.12	76.41 ± 13.02	75.94 ± 13.32	75.83 ± 13.22	0.398	0.458
A（cm/s）	66.78 ± 11.45	67.12 ± 11.83	67.54 ± 12.62	68.02 ± 11.85	68.11 ± 12.02	1.025	0.671
E/A	1.15 ± 0.23	1.14 ± 0.24	1.13 ± 0.23	1.12 ± 0.21	1.11 ± 0.16	0.129	0.336
Sm（cm/s）	8.23 ± 1.58	8.14 ± 1.60	7.99 ± 1.63	7.82 ± 1.59	7.47 ± 1.45	6.902	0.001^*
Em（cm/s）	9.23 ± 1.63	9.09 ± 1.58	8.91 ± 1.67	8.71 ± 1.74	8.52 ± 1.53	5.667	0.001^*
Am（cm/s）	8.12 ± 1.58	8.18 ± 1.61	8.24 ± 1.68	8.50 ± 1.72	8.93 ± 1.75	6.891	0.001^*
Em/Am	1.14 ± 0.05	1.11 ± 0.07	1.08 ± 0.06	1.02 ± 0.06	0.97 ± 0.03	8.471	0.001^*
E/Em	8.25 ± 1.01	8.42 ± 1.07	8.85 ± 1.22	9.30 ± 1.40	9.63 ± 1.51	11.324	0.001^*
LAVI（mL/m²）	22.33 ± 3.37	24.37 ± 3.59	26.80 ± 2.45	29.15 ± 2.89	32.57 ± 4.94	18.323	0.001^*
与治疗前比较，^*P < 0.05。

下载: 导出CSV

表 2 分析不同治疗周期的3D-STI心脏指标[（$\bar x \pm s $），%]

Table 2. Analysis of 3D-STI cardiac indicators in different treatment cycles [（$\bar x \pm s $），%]

指标	治疗前	治疗3个月	治疗6个月	治疗9个月	治疗12个月	F	P
LVEF	61.21 ± 3.58	58.54 ± 3.16	56.63 ± 3.84	55.26 ± 3.71	54.38 ± 3.25	18.325	0.001^*
GLS	−22.89 ± 2.49	−19.41 ± 2.35	−17.38 ± 2.14	−15.82 ± 2.01	−13.15 ± 1.96	9.258	0.001^*
GRS	46.58 ± 4.74	43.58 ± 4.05	40.74 ± 3.52	37.96 ± 3.21	35.16 ± 3.10	12.416	0.001^*
LVtw	−12.59 ± 1.16	−11.93 ± 1.16	−10.88 ± 1.18	−9.73 ± 1.15	−9.55 ± 1.14	11.872	0.001^*
GCS	−18.59 ± 2.15	−17.99 ± 1.65	−16.84 ± 1.85	−15.92 ± 1.73	−14.06 ± 1.64	10.215	0.001^*
GAS	−34.45 ± 3.12	−30.47 ± 3.39	−26.15 ± 2.63	−24.16 ± 2.51	−20.09 ± 2.31	14.525	0.001^*
与治疗前比较，^*P < 0.05。

下载: 导出CSV

参考文献(20)

[1]	孙文婧,胡曼婷,李娜,葛菲,陈文林,刘洋. 乳腺癌内分泌治疗耐药及其逆转的研究进展[J]. 昆明医科大学学报,2021,42(07):143-149.
[2]	刘安生,魏虹,商志娟,等. 超声心动图评估化疗药物对乳腺癌患者左心房结构,机械功能和机械离散度的影响[J]. 中国循环杂志,2020,35(12):1212-1215. doi: 10.3969/j.issn.1000-3614.2020.12.009
[3]	Gripp E A,Oliveira G E,Feijó L A,et al. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment[J]. Arquivos brasileiros de cardiologia,2018,110:140-150.
[4]	Puckett L L,Saba S G,Henry S,et al. Cardiotoxicity screening of long‐term,breast cancer survivors—The CAROLE (Cardiac‐Related Oncologic Late Effects) Study[J]. Cancer medicine,2021,10(15):5051-5061. doi: 10.1002/cam4.4037
[5]	Timóteo A T,Moura Branco L,Filipe F,et al. Cardiotoxicity in breast cancer treatment: what about left ventricular diastolic function and left atrial function?[J]. Echocardiography,2019,36(10):1806-1813. doi: 10.1111/echo.14487
[6]	蒋瑶,牟霜,谭开彬. 二维斑点追踪成像评价乳腺癌曲妥珠单抗化疗亚临床心脏毒性的价值[J]. 临床超声医学杂志,2020,22(1):33-37. doi: 10.3969/j.issn.1008-6978.2020.01.012
[7]	Anthony F Y,Ho A Y,Braunstein L Z,et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy[J]. Journal of the American Society of Echocardiography,2019,32(4):521-528. doi: 10.1016/j.echo.2018.12.009
[8]	Gulati G,Zhang K W,Scherrer-Crosbie M,et al. Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab[J]. Current Heart Failure Reports,2014,11(4):366-373. doi: 10.1007/s11897-014-0214-8
[9]	Bouwer N I,Jager A,Liesting C,et al. Cardiac monitoring in HER2-positive patients on trastuzumab treatment:A review and implications for clinical practice[J]. The Breast,2020,52:33-44. doi: 10.1016/j.breast.2020.04.005
[10]	Chen J,Wang L,Wu F F,et al. Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy[J]. Echocardiography,2019,36(9):1682-1688. doi: 10.1111/echo.14467
[11]	Chang W T,Feng Y H,Kuo Y H,et al. Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer—from bedside to bench[J]. International Journal of Cardiology,2020,311:64-70. doi: 10.1016/j.ijcard.2020.01.036
[12]	Abu-Khalaf M M,Safonov A,Stratton J,et al. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy[J]. Breast Cancer Research and Treatment,2019,176(2):261-270. doi: 10.1007/s10549-019-05178-z
[13]	董百惠,姜红,肖响,等. 乳腺癌患者蒽环类续贯曲妥珠单抗治疗期间超声心动图监测执行度分析[J]. 中国药物警戒,2022,19(5):557-560.
[14]	刘志月,刘梅,黄鹤,等. 实时三维超声心动图及三维斑点追踪技术评估左心室射血分数保留的多发性骨髓瘤患者左心房功能的价值[J]. 临床心血管病杂志,2021,37(10):936-942.
[15]	胡夕春,张剑,陈德滇,等. 中国蒽环类药物治疗乳腺癌专家共识[J]. 中国肿瘤临床,2018,45(3):120-125. doi: 10.3969/j.issn.1000-8179.2018.03.198
[16]	李捷,郭冠军,杨益宁,等. 三维斑点追踪超声心动图对老年心力衰竭患者左心室舒张功能的评估价值[J]. 中国医师杂志,2021,23(11):1673-1676. doi: 10.3760/cma.j.cn431274-20200906-01237
[17]	Kosku H,Kaya C T,Sengul S,et al. The diastolic function abnormalities in hemodialysis session: a two-dimensional speckle tracking echocardiographic (2DSTE) study[J]. The International Journal of Cardiovascular Imaging,2022,38(7):1453-1461. doi: 10.1007/s10554-022-02535-w
[18]	Ebik M,Tatekin N,M Gürdoan,et al. fri0058 the importancn of speckle trackizg echocardiography in the evaluation of cardiac functions in patients with rheumatoid arthritis[J]. Annals of the Rheumatic Diseases,2020,79(1):605-606.
[19]	胡滨,礼广森,黄冬梅,等. 三维斑点追踪技术评价含曲妥珠单抗化疗方案对HER-2阳性乳腺癌患者左室功能的影响[J]. 临床超声医学杂志,2020,22(8):622-625. doi: 10.3969/j.issn.1008-6978.2020.08.021
[20]	杜晓,袁莉. 实时三维斑点追踪技术在中老年急性心肌梗死患者经皮冠状动脉介入治疗术后左心室整体收缩功能评估中的应用价值[J]. 中国药物与临床,2020,20(8):1245-1247.

相关文章(20)

[1]	张正, 杨艳红, 冯再辉, 詹路江, 普金仙, 段茜婷. 高场强MRIT1灌注成像联合DWI成像在评估乳腺癌新辅助化疗疗效中的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240722
[2]	陈雪梅, 郭品, 钏刘芳, 王梓, 李雪娇, 何文姬. 基于Tei指数评价蒽环类药物对急性白血病患儿心脏毒性的研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240216
[3]	潘水水, 白劲松, 李重熙, 艾志琼, 田波, 母昌垒, 刘怡涵, 刘俊. HIV/AIDS患者超声心动图异常的影响因素分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230422
[4]	他林昆, 黄燕玲, 张静秋, 陆永萍. 超声心动图不同切面诊断胎儿先天性血管环的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220615
[5]	孙文婧, 胡曼婷, 李娜, 葛菲, 陈文林, 刘洋. 乳腺癌内分泌治疗耐药及其逆转的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210724
[6]	赵娟, 涂腾灿, 杨梅君, 张小勇, 潘伟. 急性冠状动脉综合征患者早期冠状动脉病变的评估, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211219
[7]	魏骊铮, 闵杰青, 田锦润, 曹彦洁, 潘鹏, 王鹏, 杨云娟, 罗云娇. 云南省婴幼儿不完全性川崎病急性期超声心动图特征, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210923
[8]	他林昆, 黄燕玲, 陆永萍. 超声心动图诊断胎儿法洛四联症的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210126
[9]	李宁, 徐妙, 张维, 张倩, 孔鹰. 乳腺癌患者放化疗前后维生素D水平的变化, 昆明医科大学学报.
[10]	叶学群, 聂磊. 超声心动图结合动态心电图诊断冠心病合并心力衰竭的价值, 昆明医科大学学报.
[11]	王怡茗, 杨越. 乳腺钼靶和超声检查对于诊断乳腺癌的价值对比, 昆明医科大学学报.
[12]	郭学君, 缪春梅, 汤清雯, 金学梅, 杨越. 乳腺癌患者甲状腺超声影像的占位性改变, 昆明医科大学学报.
[13]	李云芬. CCDC8基因表达与乳腺癌分子分型的相关性研究, 昆明医科大学学报.
[14]	李晓勇. Th17/Treg平衡失调及其相关因子在乳腺癌浸润转移的相关性研究, 昆明医科大学学报.
[15]	赵春芳. 干扰RNA抑制EGFR对乳腺癌细胞放射敏感性的影响, 昆明医科大学学报.
[16]	贺光林. 心肌重构水平监测在慢性心衰患者病情评估中的临床意义, 昆明医科大学学报.
[17]	韩江琼. 多西紫杉醇与紫杉醇联合吡柔比星和环磷酰胺在局部进展期乳腺癌化疗中致心脏毒性的观察, 昆明医科大学学报.
[18]	陈贤玉. 曲妥珠单抗1治疗HER-2过表达乳腺癌的研究进展, 昆明医科大学学报.
[19]	吴安玥. 简体中文版MOS-HIV量表对HIV感染者/AIDS病人生活质量的评估, 昆明医科大学学报.
[20]	李昆仑. RNAi抑制Survivin基因的表达对乳腺癌SKBr-3细胞的影响, 昆明医科大学学报.